Denmark’s Leo Pharma is pushing back its planned initial public offering to beyond 2026, citing market volatility and conditions it says are not yet suitable. The company’s CEO, Christophe Bourdon, says the owners are not proceeding under the current timing outlook and declines to provide a new specific timeline.

Both outlets report that Leo Pharma was previously considering a listing this year, but the company is now moving that target further out. The coverage aligns on the core message: the IPO is delayed rather than cancelled, and the decision is tied to external market conditions rather than a change in business strategy. The main difference in framing is that Quartz emphasizes the owners’ assessment of volatility and the lack of a revised date, while Bloomberg highlights the postponement relative to an earlier 2026-plus goal and the shifting listing schedule.